Table 1 Clinical and treatment characteristics of the patients
Median | Range | |
Age at diagnosis (years) | 70 | 58~81 |
Gland volume (mL) | 33.4 | 27~62 |
Follow-up (months) | 90 | 12~186 |
Count | Percentage (%) | |
Clinical stage | ||
T2b | 23 | 7.2 |
T2c | 167 | 52.2 |
T3a | 82 | 25.6 |
T3b | 48 | 15 |
Gleason score | ||
≤6 | 3 | 0.9 |
7 | 11 | 3.4 |
≥8 | 306 | 95.6 |
PSA at diagnosis (ng/mL) | ||
≤10 | 35 | 10.9 |
10~20 | 49 | 15.3 |
≥20 | 236 | 73.8 |
Memorial Sloan-Kettering risk classification | ||
2~3 IS | 71 | 22.2 |
1 HS | 106 | 33.1 |
2~3 HS | 143 | 44.7 |
MAB | ||
Continuous | 184 | 57.5 |
Intermittent | 136 | 42.5 |
PPB | ||
Yes | 203 | 63.4 |
No | 117 | 36.6 |
PSA nadir (ng/mL) | ||
≤1.0 | 241 | 75.3 |
>1.0 | 79 | 24.7 |
Time to PSA nadir (months) | ||
≤3 | 207 | 64.7 |
>3 | 113 | 35.3 |
PSA doubling time (months) | ||
≤12 | 46 | 14.4 |
>12 | 274 | 85.6 |
PSA decrease (%) | ||
<90 | 71 | 22.2 |
≥90 | 249 | 77.8 |